Rodeo Therapeutics raises $5.9M to develop small-molecule 15-PGDH inhibitors for tissue regeneration
Rodeo Therapeutics, a Seattle biotech founded by Case Western and UT researchers, raised $5.9 million to develop small-molecule drugs that stimulate the body’s natural tissue-regeneration processes. Its initial programs target inflammatory bowel disease and hematopoietic recovery after bone marrow transplants by inhibiting the enzyme 15-PGDH.